Case of hypophysitis caused by nivolumab

Journal of Dermatology

Volumn 44, Issue 1, 2017, Pages 109-110

  Ishikawa, Masashi ^a   Oashi, Kohei ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DACARBAZINE; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; NIVOLUMAB; OXYGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADRENAL INSUFFICIENCY; ADRENAL METASTASIS; ADULT; ANOREXIA; CASE REPORT; DEPRESSED BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LETTER; MALAISE; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; CONJUNCTIVA; DIAGNOSTIC IMAGING; HORMONE SUBSTITUTION; INTERSTITIAL LUNG DISEASE; TREATMENT WITHDRAWAL;

ADRENAL INSUFFICIENCY; ADRENOCORTICOTROPIC HORMONE; ANOREXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CONJUNCTIVA; DACARBAZINE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; HYPOPHYSITIS; HYPOTHYROIDISM; LUNG DISEASES, INTERSTITIAL; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; MYALGIA; NAUSEA; PROGRAMMED CELL DEATH 1 RECEPTOR; WITHHOLDING TREATMENT;

EID: 84971220814     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13437     Document Type: Letter

References (5)

1. Topalian SL, Sznol M, McDermott DF et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol 2014; 32: 1020–1030.
2. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384.
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23–34.
4. Faje AT, Sullivan R, Lawrence D et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99: 4078–4085.
5. Albarel F, Gaudy C, Castinetti F et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015; 172: 195–204.